

# Miguel Saceda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3144416/publications.pdf>

Version: 2024-02-01

45  
papers

1,732  
citations

304368

22  
h-index

288905

40  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2118  
citing authors

#	ARTICLE	IF	CITATIONS
1	Biomedical application of small extracellular vesicles in cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114117.	6.6	19
2	CLytA-DAAO Chimeric Enzyme Bound to Magnetic Nanoparticles. A New Therapeutical Approach for Cancer Patients?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1477.	1.8	10
3	Cell Death Mechanisms Induced by CLytA-DAAO Chimeric Enzyme in Human Tumor Cell Lines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8522.	1.8	8
4	Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. <i>Cancers</i> , 2020, 12, 3717.	1.7	21
5	CLytA-DAAO, Free and Immobilized in Magnetic Nanoparticles, Induces Cell Death in Human Cancer Cells. <i>Biomolecules</i> , 2020, 10, 222.	1.8	19
6	Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3. <i>PLoS ONE</i> , 2019, 14, e0212581.	1.1	33
7	PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines. <i>Cells</i> , 2018, 7, 131.	1.8	17
8	Liver damage and caspase-dependent apoptosis is related to protein malnutrition in mice: Effect of methionine. <i>Acta Histochemica</i> , 2015, 117, 126-135.	0.9	5
9	HGUE-C-1 is an atypical and novel colon carcinoma cell line. <i>BMC Cancer</i> , 2015, 15, 240.	1.1	6
10	Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation. <i>Neoplasia</i> , 2014, 16, 845-860.	2.3	31
11	Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma. <i>Cells</i> , 2014, 3, 199-235.	1.8	65
12	Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?. <i>Translational Oncology</i> , 2014, 7, 590-604.	1.7	30
13	Dual regulation of P-glycoprotein expression by Trichostatin A in cancer cell lines. <i>BMC Molecular Biology</i> , 2012, 13, 25.	3.0	15
14	Acquisition of MDR phenotype by leukemic cells is associated with increased caspase-3 activity and a collateral sensitivity to cold stress. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 1416-1425.	1.2	8
15	Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. <i>Experimental Cell Research</i> , 2011, 317, 1476-1489.	1.2	47
16	Serine Proteases in Histone Deacetylase Inhibitor-Induced Apoptosis Still an Unresolved Question – Response. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2441-2442.	1.9	4
17	Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level. <i>Cancer Letters</i> , 2010, 290, 192-203.	3.2	54
18	Post-transcriptional Regulation of P-Glycoprotein Expression in Cancer Cell Lines. <i>Molecular Cancer Research</i> , 2007, 5, 641-653.	1.5	37

#	ARTICLE	IF	CITATIONS
19	Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1877-1885.	1.2	10
20	Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines. <i>Oncogene</i> , 2007, 26, 7185-7193.	2.6	63
21	Tumour cells resistance in cancer therapy. <i>Clinical and Translational Oncology</i> , 2007, 9, 13-20.	1.2	24
22	Molecular biology of exocrine pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2006, 8, 306-312.	1.2	6
23	Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2172-2181.	1.9	37
24	Differentiation and drug resistance relationships in leukemia cells. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 98-108.	1.2	10
25	Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1222-1230.	1.9	57
26	Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol. <i>Journal of Endocrinology</i> , 2004, 180, 487-496.	1.2	21
27	Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. <i>Journal of Endocrinology</i> , 2004, 180, 497-504.	1.2	69
28	Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. <i>International Journal of Cancer</i> , 2003, 104, 579-586.	2.3	35
29	Role of insulin-like growth factor-I in regulating estrogen receptor- $\alpha$ gene expression. , 2000, 76, 605-614.		78
30	Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. <i>Journal of Endocrinology</i> , 2000, 165, 371-378.	1.2	74
31	Regulation of estrogen receptor- $\alpha$ gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. <i>Journal of Cellular Biochemistry</i> , 1999, 75, 640-651.	1.2	79
32	Estradiol regulates estrogen receptor mRNA stability. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998, 66, 113-120.	1.2	67
33	The Role of Transforming Growth Factor- $\beta$ 2 in the Regulation of Estrogen Receptor Expression in the MCF-7 Breast Cancer Cell Line. <i>Endocrinology</i> , 1997, 138, 1498-1505.	1.4	46
34	Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells. <i>International Journal of Cancer</i> , 1995, 63, 560-567.	2.3	71
35	Effects of 12-O-Tetradecanoylphorbol-13-acetate on Estrogen Receptor Activity in MCF-7 Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 25244-25251.	1.6	34
36	Regulation of estrogen receptor expression. <i>Breast Cancer Research and Treatment</i> , 1994, 31, 183-189.	1.1	17

#	ARTICLE	IF	CITATIONS
37	Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. <i>Journal of Cellular Physiology</i> , 1993, 157, 110-118.	2.0	37
38	Regulation of Estrogen Receptor Expression in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 1993, 330, 143-153.	0.8	19
39	Estrogen and progesterone receptors. <i>Cancer Treatment and Research</i> , 1991, , 273-288.	0.2	2
40	Role of an Estrogen Receptor-Dependent Mechanism in the Regulation of Estrogen Receptor mRNA in MCF-7 Cells. <i>Molecular Endocrinology</i> , 1989, 3, 1782-1787.	3.7	90
41	Regulation of Breast Cancer Cells by Hormones and Growth Factors: Effects on Proliferation and Basement Membrane Invasiveness. <i>Hormone Research</i> , 1989, 32, 242-249.	1.8	11
42	Regulation of the Estrogen Receptor in MCF-7 Cells by Estradiol. <i>Molecular Endocrinology</i> , 1988, 2, 1157-1162.	3.7	308
43	Impairment of insulin release by methylation inhibitors. <i>Biochemical Pharmacology</i> , 1984, 33, 2033-2039.	2.0	18
44	Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. , 0, .		5
45	The Role of Transforming Growth Factor- $\beta$ 2 in the Regulation of Estrogen Receptor Expression in the MCF-7 Breast Cancer Cell Line. , 0, .		15